阿帕替尼三线治疗晚期结肠癌的临床分析

Clinical Analysis of Third-line Treatment of Advanced Colon Cancer with Apatinib

目的探讨甲磺酸阿帕替尼三线治疗晚期结肠癌的疗效和安全性。方法回顾性分析于2017年1月—2019年6月在平邑县人民医院治的56例晚期结肠癌患者资料,所有患者均给予初始剂量500 mg/d阿帕替尼单药治疗,并定期随访,记录药物治疗的远期疗效、近期疗效和安全性。结果全组56例患者中位无进展生存期(mPFS)为4.1个月,中位总生存时间(mOS)为7.2个月。治疗1个月后56例患者均可行疗效评价,其中部分缓解(PR)7例,疾病稳定(SD)23例,病情进展(PD)26例,ORR为12.5%,DCR为53.6%。主要不良反应为乏力(50.0%)和食欲减退(42.9%),其次为继发性高血压(35.7%)、手足综合征(35.7%)、蛋白尿(28.6%)、白细胞减少(39.3%)、血小板减少(32.1%),大多经剂量调整或对症治疗后缓解。结论甲磺酸阿帕替尼三线治疗晚期结肠癌具有良好的临床获益,且不良反应可控。

Objective To investigate the efficacy and safety of apatinib mesylate in third-line treatment of advanced colon cancer.Methods The case data of 56 patients with advanced colon cancer treated in Pingyi County People's Hospital from January 2017 to June 2019 were retrospectively analyzed.All patients were given apatinib monotherapy at an initial dose of 500 mg/d and were followed up regularly.Long-term efficacy,short-term efficacy and safety of drug therapy were recorded.Results The median progression-free survival time(mPFS)of the 56 patients in the whole group was 4.1 months,and the median overall survival time(mOS)was 7.2 months.After 1 month of treatment,all 56 patients were evaluated for efficacy,including 7 patients with partial remission(PR),23 patients with stable disease(SD),and 26 patients with progressive disease(PD),the ORR was 12.5%,and the DCR was 53.6%.The main adverse reactions were fatigue(50.0%)and loss of appetite(42.9%),followed by secondary hypertension(35.7%),hand-foot syndrome(35.7%),proteinuria(28.6%),leukopenia(39.3%),thrombocytopenia(32.1%).Most of them were relieved after dose adjustment or symptomatic treatment.Conclusion Apatinib mesylate in the third-line treatment of advanced colon cancer has good clinical benefits and controllable adverse reactions.